The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 11, 2018
Filed:
Nov. 21, 2013
Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;
Centre National DE LA Recherche Scientifique (Cnrs), Paris, FR;
Assistance Publique—hopitaux DE Paris, Paris, FR;
Université Paris Descartes, Paris, FR;
Imagine Institut Des Maladies Genetiques Necker Enfants Malades, Paris, FR;
Olivier Hermine, Paris, FR;
Marie Thérèse Rubio, Paris, FR;
Marie Bouillie, Paris, FR;
Maria Leite de Maraes, Paris, FR;
Institut National de la Sante et de la Recherche Medicale (INSERM), Paris, FR;
Centre National de la Recherche Scientifique (CNRS), Paris, FR;
Assistance Publique—Hopitaux de Paris, Paris, FR;
Universite Paris Descartes, Paris, FR;
Imagine Institut des Maladies Genetiques Necker Enfants Malades, Paris, FR;
Abstract
The present invention relates to a method for determining whether a candidate human transplant donor is at risk of inducing acute graft versus host disease (aGVHD) in a human transplant recipient, which may in turn allow the selection of a donor exhibiting no risk for the recipient. The present invention also relates to a method for adjusting the immunosuppressive treatment administered to a human transplanted recipient following its graft transplantation after having performing the method for determining risk of the invention. The methods comprise expanding the candidate donor's iNKT cells (invariant NKT cells) and determining the presence or absence of expansion of the CD4(−) iNKT cell sub-population. In particular, CD3+CD4− TCRV[alpha]24V[beta]11 cells are determined. Kits are disclosed.